On June 26, 2023 IDP Pharma, based in Barcelona’s Science Park (PCB) and a pioneer in the development of drugs targeting intrinsically disordered proteins (IDPs), reported the starting of clinical trial of its first-in-class drug IDP-121, first to degrade cMyc oncoprotein, a Holy Grail oncogene long-quested by the pharma industry (Press release, IDP Pharma, JUN 26, 2023, View Source;utm_medium=rss&utm_campaign=idp-pharma-starts-the-clinical-trial-of-idp-121-the-first-drug-that-degrades-the-oncogene-cmyc-a-key-disease-driver-responsible-for-the-initiation-and-progression-of-several-hematological-tumors [SID1234632892]). The study will include patients with diffuse lymphoma, chronic lymphocytic leukaemia and multiple myeloma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!